[시장보고서]글리코믹스 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

글리코믹스 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Glycomic Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

상품코드 : 1495360

리서치사 : Persistence Market Research

발행일 : 2024년 06월

페이지 정보 : 영문 306 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 글리코믹스 치료 시장을 상세 분석하고 복잡한 역학과 향후 궤도에 관한 인사이트를 제공하고 있습니다. 시장 동향부터 성장 촉매, 저해요인, 신규 패턴까지 2024- 2032년까지의 귀중한 통계와 예측을 제공합니다.

주요 인사이트

글리코믹스 치료 시장 규모(2024년) : 1,676억 1,567만 달러
예측 시장 금액(2032년) 5,517억 5,600만 달러
세계 시장 성장률(CAGR 2024-2032년) : 16.1%

글리코믹스 치료 시장 - 리포트 범위 :

글리코믹스 치료 시장에는 의약품, 바이오테크놀러지, 헬스케어 등의 산업에 걸친 다양한 용도가 포함됩니다. 글리코믹스 치료에는 치료 목적을 위한 당쇄(당) 연구와 조작이 포함됩니다. 이 치료제는 백신, 암 치료 및 전염병 치료제의 개발에 중요한 역할을 하고 있습니다. 이 시장은 제약회사, 생명공학 기업, 연구기관 등 다양한 최종사용자를 대상으로 질병 치료 및 예방을 위한 첨단 솔루션을 제공합니다. 시장 성장의 원동력은 기술 발전, 표적 치료에 대한 수요 증가, 헬스케어 연구에 대한 투자 증가 등의 요인에 기인합니다.

시장 성장 촉진요인 :

세계 글리코믹스 치료 시장은 몇 가지 주요 성장 촉진요인에 의해 지원되고 있습니다. 글리코믹스의 기술 발전은 당 사슬에 대한 이해와 조작을 향상시키고 새로운 치료제의 개발을 촉진합니다. 또한 표적 치료 및 맞춤 의료에 대한 수요가 증가함에 따라 글리코믹스 치료에 대한 수요가 크게 증가하고 있습니다. 또한 헬스케어 연구개발에 대한 투자 증가는 글리코믹스의 새로운 치료용도 발견을 촉진하여 시장 성장을 더욱 촉진할 것입니다.

시장 성장 억제요인 :

유망한 성장 전망에도 불구하고, 글리코믹스 치료 시장은 높은 R&D 비용, 규제 장벽, 대체 요법과의 경쟁과 관련된 문제에 직면해 있습니다. 글리코믹스의 구조와 기능이 복잡하기 때문에 연구개발에 많은 투자가 필요하며, 이는 시장 진출기업에게 재정적 어려움을 야기합니다. 치료제 개발 및 승인에 대한 엄격한 규제 요건은 규정 준수에 대한 부담을 가중시켜 시장 확대에 영향을 미칩니다. 또한 유전체학 및 프로테오믹스와 같은 다른 치료 접근법과의 경쟁은 글리코믹스 치료의 보급에 도전이 되고 있습니다.

시장 기회 :

기술 혁신, 산업 제휴, 시장 다변화로 인해 글리코믹스 치료 시장은 성장의 기회를 맞이하고 있습니다. 맞춤 의료, 면역 요법, 합성 생물학 등의 새로운 트렌드는 제조업체들이 글리코믹스 치료제의 새로운 제형과 용도를 모색하도록 유도하고 있습니다. 또한 전략적 파트너십, 공동연구, 인수합병(M&A)을 통해 시장 기업은 제품 포트폴리오를 확장하고, 기술 역량을 강화하며, 주요 지역에서 시장 입지를 강화하고 있습니다. 또한 헬스케어 연구에 대한 투자 증가와 기술 혁신 및 산업 인프라에 대한 정부 지원 증가는 시장 확대와 다각화를 촉진하는 환경을 조성하고 있습니다.

이 보고서에서 다룬 주요 질문

세계 글리코믹스 치료 시장의 성장을 가속하는 주요 요인은?
기술 발전과 산업 동향은 글리코믹스 치료의 응용과 제형의 진화를 어떻게 형성하고 있는가?
글리코믹스 치료 분야 시장 진출기업이 직면한 주요 과제와 기회는 무엇인가?
글리코믹스 치료제 제조업체에게 가장 높은 성장 잠재력을 제공하는 산업 부문과 지역은?
경쟁 구도에서 글리코믹스 치료제를 차별화하고 시장 점유율을 확보하기 위해 주요 기업은 어떤 전략을 채택하고 있는가?

서론/주요 조사 결과
시장 규모 금액(100만 달러)의 실적 분석 : 클래스별, 2019-2023년
현재 및 향후 시장 규모 금액(100만 달러)의 분석과 예측 : 클래스별, 2024-2032년
- 고립
- 합성
전년대비 성장 동향 분석 : 클래스별, 2019-2023년
절대$기회 분석 : 클래스별, 2024-2032년

제6장 세계의 글리코믹스 치료 시장 분석 : 적응증별

서론/주요 조사 결과
시장 규모 금액(100만 달러)의 실적 분석 : 적응증별, 2019-2023년
현재 및 향후 시장 규모 금액(100만 달러)의 분석과 예측 : 적응증별, 2024-2032년
- 혈전증·화학 예방
- 빈혈
- 항유착성·항염증성
- 백내장
- 고셰병
- MPS-1·IV
- 암
- 알츠하이머병
- 인플루엔자 A형·B형
- 기타
전년대비 성장 동향 분석 : 적응증별, 2019-2023년
절대$기회 분석 : 적응증별, 2024-2032년

제7장 세계의 글리코믹스 치료 시장 분석 : 구조별

서론/주요 조사 결과
시장 규모 금액(100만 달러)의 실적 분석 : 구조별, 2019-2023년
현재 및 향후 시장 규모 금액(100만 달러)의 분석과 예측 : 구조별, 2024-2032년
- 당단백질
- 시알산 표적화
- Zanamivir
- Oseltamivir ㅍProteoglycans
- Glycosylphosphatidylinositol - 앵커 단백질 및 헤파린 기반 당쇄
- Glycosaminoglycans 표적화
- Glycosphingolipids 표적화
- 기타 - Acarbose, Alglucosidase Alfa, Allosamidin
전년대비 성장 동향 분석 : 구조별, 2019-2023년
절대$기회 분석 : 구조별, 2024-2032년

제8장 세계의 글리코믹스 치료 시장 분석 : 작용기서별

서론/주요 조사 결과
시장 규모 금액(100만 달러)의 실적 분석 : 작용기서별, 2019-2023년
현재 및 향후 시장 규모 금액(100만 달러)의 분석과 예측 : 작용기서별, 2024-2032년
- 뉴라미니다아제를 저해
- 에리스로포이에틴과 효소 보충 요법 - ERT
- 조직 플라스미노겐 활성화인자
- Glucosylceramide 합성효소 저해
- 인터류킨 1, 2, 3
- β및γ 인터페론
전년대비 성장 동향 분석 : 작용기서별, 2019-2023년
절대$기회 분석 : 작용기서별, 2024-2032년

제9장 세계의 글리코믹스 치료 시장 분석 : 지역별

서론/주요 조사 결과
시장 규모 금액(100만 달러)의 실적 분석 : 지역별, 2019-2023년
현재 및 향후 시장 규모 금액(100만 달러)의 분석과 예측 : 지역별, 2024-2032년
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동 및 아프리카
시장의 매력 분석 : 지역별

제10장 북미의 글리코믹스 치료 시장 분석 : 국가별

제11장 라틴아메리카의 글리코믹스 치료 시장 분석 : 국가별

제12장 유럽의 글리코믹스 치료 시장 분석 : 국가별

제13장 아시아태평양의 글리코믹스 치료 시장 분석 : 국가별

제14장 중동 및 아프리카의 글리코믹스 치료 시장 분석 : 국가별

제15장 주요 국가의 글리코믹스 치료 시장 분석

미국
캐나다
브라질
멕시코
독일
영국
프랑스
스페인
이탈리아
중국
일본
한국
싱가포르
태국
인도네시아
호주
뉴질랜드
GCC 국가
남아프리카공화국
이스라엘

제16장 시장 구조 분석

경쟁 대시보드
경쟁 벤치마킹
주요 기업의 시장 점유율 분석

제17장 경쟁 분석

경쟁의 상세
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc.
- Sanofi
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc.
- GlycoMar
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd

제18장 사용되는 가정과 두자어

제19장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research presents an in-depth analysis of the Glycomic Therapeutics Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2032.

Key Insights:

Glycomic Therapeutics Market Size (2024): USD 167615.67 Million
Projected Market Value (2032): USD 551756 Million
Global Market Growth Rate (CAGR 2024 to 2032): 16.1%

Glycomic Therapeutics Market - Report Scope:

The Glycomic Therapeutics Market encompasses various applications across industries such as pharmaceuticals, biotechnology, and healthcare. Glycomic therapeutics involve the study and manipulation of glycans (sugars) for therapeutic purposes. These therapeutics play a crucial role in the development of vaccines, cancer treatments, and therapies for infectious diseases. This market caters to a wide range of end-users, including pharmaceutical companies, biotech firms, and research institutions, offering advanced solutions for disease treatment and prevention. Market growth is driven by factors such as technological advancements, increasing demand for targeted therapies, and rising investment in healthcare research.

Market Growth Drivers:

The global Glycomic Therapeutics Market is bolstered by several key growth drivers. Technological advancements in glycomics enhance the understanding and manipulation of glycans, driving the development of novel therapeutics. Moreover, the increasing demand for targeted and personalized medicine creates significant demand for glycomic therapeutics. Additionally, the growing investment in healthcare research and development stimulates the discovery of new therapeutic applications for glycans, further propelling market growth.

Market Restraints:

Despite its promising growth prospects, the Glycomic Therapeutics Market faces challenges related to high research and development costs, regulatory hurdles, and competition from alternative therapies. The complexity of glycan structures and functions requires substantial investment in research and development, posing financial challenges for market players. Stringent regulatory requirements regarding therapeutic development and approval impose compliance burdens, impacting market expansion. Furthermore, competition from other therapeutic approaches, such as genomics and proteomics, poses challenges to the widespread adoption of glycomic therapeutics.

Market Opportunities:

The Glycomic Therapeutics Market presents lucrative growth opportunities driven by technological innovation, industry collaborations, and market diversification. Emerging trends such as personalized medicine, immunotherapy, and synthetic biology inspire manufacturers to explore new formulations and applications for glycomic therapeutics. Moreover, strategic partnerships, research collaborations, and mergers and acquisitions enable market players to expand their product portfolios, enhance their technical capabilities, and strengthen their market presence in key regions. Furthermore, growing investments in healthcare research, coupled with increasing government support for innovation and industrial infrastructure, create a conducive environment for market expansion and diversification.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Glycomic Therapeutics Market globally?
How are technological advancements and industry trends shaping the evolution of glycomic therapeutics applications and formulations?
What are the key challenges and opportunities facing market participants in the glycomic therapeutics segment?
Which industrial sectors and geographic regions offer the highest growth potential for glycomic therapeutics manufacturers?
What strategies are leading companies employing to differentiate their glycomic therapeutics offerings and capture market share in the competitive healthcare landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Glycomic Therapeutics Market, including pharmaceutical companies, biotech firms, and research institutions, focus on innovation, product differentiation, and market expansion to gain a competitive edge. These companies invest in research and development to develop advanced glycan manipulation technologies, improve therapeutic efficacy, and explore new applications for glycomic therapeutics. Moreover, strategic collaborations with research institutions, academic partners, and industry associations enable market players to access new technologies, expand their knowledge base, and accelerate product development efforts. Furthermore, emphasis on regulatory compliance, quality assurance, and customer support enhances brand reputation and fosters long-term relationships with customers and stakeholders.

Key Companies Profiled:

GlycoMimetics, Inc.
Protalix BioTherapeutics, Inc.
Angion Biomedica Corp.
Oxford GlycoSciences Ltd.
GlycoNet
GlycoThera GmbH
Z Biotech, LLC
Sanguine BioSciences, Inc.
GLYcoDiag
Genentech, Inc.
Novartis AG
Eli Lilly and Company

Glycomic Therapeutics Market Research Segmentation:

By Class:

Isolated
Synthetic

By Structures:

Glycoproteins
Targeting Sialic Acid
Proteoglycans
Targeting Glycosaminoglycans
Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
Targeting Glycosphingolipids
Others

By Indications:

Thrombosis and Chemoprophylaxis
Anaemia
Anti-adhesive and Anti-inflammatory
Cataracts
Gaucher's disease
MPS-1 and IV
Cancer
Alzheimer's disease
Influenza type A and B
Others

By Mode of Action:

Inhibits Neuraminidase
Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
Erythropoietin and Enzyme Replacement Therapy
Tissue Plasminogen Activator
Inhibits Glucosylceramide Synthase
Interleukin 1, 2 & 3
Beta and Gamma Interferons
Others

By Region:

North America
Latin America
Asia Pacific
MEA
Europe

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter's Analysis
3.6. Regulatory Landscape
- 3.6.1. By Key Regions
- 3.6.2. By Key Countries
3.7. Regional Parent Market Outlook

4. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast, 2024-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2032
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis

5. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Class

5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Class, 2019-2023
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Class, 2024-2032
- 5.3.1. Isolated
- 5.3.2. Synthetic
5.4. Y-o-Y Growth Trend Analysis By Class, 2019-2023
5.5. Absolute $ Opportunity Analysis By Class, 2024-2032

6. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Indication

6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2019-2023
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2024-2032
- 6.3.1. Thrombosis and Chemoprophylaxis
- 6.3.2. Anaemia
- 6.3.3. Anti-adhesive and Anti-inflammatory
- 6.3.4. Cataract
- 6.3.5. Gaucher's Diseases
- 6.3.6. MPS-1 & IV
- 6.3.7. Cancer
- 6.3.8. Alzheimer's
- 6.3.9. Influenza Type A and B
- 6.3.10. Others
6.4. Y-o-Y Growth Trend Analysis By Indication, 2019-2023
6.5. Absolute $ Opportunity Analysis By Indication, 2024-2032

7. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Structures

7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Structures , 2019-2023
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Structures , 2024-2032
- 7.3.1. Glycoproteins
- 7.3.2. Targeting Sialic Acid
- 7.3.3. Zanamivir
- 7.3.4. Oseltamivir
- 7.3.5. Proteoglycans
- 7.3.6. Glycosylphosphatidylinositol - Anchored Proteins and Heparin Based Glycans
- 7.3.7. Targeting Glycosaminoglycans
  - 7.3.7.1. Heparin
  - 7.3.7.2. Hyaluronan - HA
  - 7.3.7.3. Laronidase
  - 7.3.7.4. Galsulfase - Naglazyme
  - 7.3.7.5. Hyaluronidase - Cumulase
  - 7.3.7.6. Others
- 7.3.8. Targeting Glycosphingolipids
  - 7.3.8.1. Imiglucerase - Cerezyme
  - 7.3.8.2. Agalsidase - Fabrazyme
  - 7.3.8.3. N-butyl-deoxynojirimycin - DNJ
  - 7.3.8.4. Others
- 7.3.9. Others - Acarbose, Alglucosidase Alfa, Allosamidin
7.4. Y-o-Y Growth Trend Analysis By Structures , 2019-2023
7.5. Absolute $ Opportunity Analysis By Structures , 2024-2032

8. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Mode of Action

8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By Mode of Action, 2019-2023
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Mode of Action, 2024-2032
- 8.3.1. Inhibits Neuraminidase
- 8.3.2. Erythhropoietin and Enzyme Replacement Therapy - ERT
- 8.3.3. Tissue Plasminogen Activator
- 8.3.4. Inhibits Glucosylceramide Synthase
- 8.3.5. Interleukin 1 and 2 and 3
- 8.3.6. Beta and Gamma Interferons
- 8.3.7. Others
8.4. Y-o-Y Growth Trend Analysis By Mode of Action, 2019-2023
8.5. Absolute $ Opportunity Analysis By Mode of Action, 2024-2032

9. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2032
- 9.3.1. North America
- 9.3.2. Latin America
- 9.3.3. Europe
- 9.3.4. Asia Pacific
- 9.3.5. MEA
9.4. Market Attractiveness Analysis By Region

10. North America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 10.2.1. By Country
  - 10.2.1.1. U.S.
  - 10.2.1.2. Canada
- 10.2.2. By Class
- 10.2.3. By Indication
- 10.2.4. By Structures
- 10.2.5. By Mode of Action
10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Class
- 10.3.3. By Indication
- 10.3.4. By Structures
- 10.3.5. By Mode of Action
10.4. Key Takeaways

11. Latin America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 11.2.1. By Country
  - 11.2.1.1. Brazil
  - 11.2.1.2. Mexico
  - 11.2.1.3. Rest of Latin America
- 11.2.2. By Class
- 11.2.3. By Indication
- 11.2.4. By Structures
- 11.2.5. By Mode of Action
11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Class
- 11.3.3. By Indication
- 11.3.4. By Structures
- 11.3.5. By Mode of Action
11.4. Key Takeaways

12. Europe Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 12.2.1. By Country
  - 12.2.1.1. Germany
  - 12.2.1.2. U.K.
  - 12.2.1.3. France
  - 12.2.1.4. Spain
  - 12.2.1.5. Italy
  - 12.2.1.6. Rest of Europe
- 12.2.2. By Class
- 12.2.3. By Indication
- 12.2.4. By Structures
- 12.2.5. By Mode of Action
12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Class
- 12.3.3. By Indication
- 12.3.4. By Structures
- 12.3.5. By Mode of Action
12.4. Key Takeaways

13. Asia Pacific Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 13.2.1. By Country
  - 13.2.1.1. China
  - 13.2.1.2. Japan
  - 13.2.1.3. South Korea
  - 13.2.1.4. Singapore
  - 13.2.1.5. Thailand
  - 13.2.1.6. Indonesia
  - 13.2.1.7. Australia
  - 13.2.1.8. New Zealand
  - 13.2.1.9. Rest of Asia Pacific
- 13.2.2. By Class
- 13.2.3. By Indication
- 13.2.4. By Structures
- 13.2.5. By Mode of Action
13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Class
- 13.3.3. By Indication
- 13.3.4. By Structures
- 13.3.5. By Mode of Action
13.4. Key Takeaways

14. MEA Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 14.2.1. By Country
  - 14.2.1.1. GCC Countries
  - 14.2.1.2. South Africa
  - 14.2.1.3. Israel
  - 14.2.1.4. Rest of MEA
- 14.2.2. By Class
- 14.2.3. By Indication
- 14.2.4. By Structures
- 14.2.5. By Mode of Action
14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Class
- 14.3.3. By Indication
- 14.3.4. By Structures
- 14.3.5. By Mode of Action
14.4. Key Takeaways

15. Key Countries Glycomic Therapeutics Market Analysis

15.1. U.S.
- 15.1.1. Pricing Analysis
- 15.1.2. Market Share Analysis, 2024
  - 15.1.2.1. By Class
  - 15.1.2.2. By Indication
  - 15.1.2.3. By Structures
  - 15.1.2.4. By Mode of Action
15.2. Canada
- 15.2.1. Pricing Analysis
- 15.2.2. Market Share Analysis, 2024
  - 15.2.2.1. By Class
  - 15.2.2.2. By Indication
  - 15.2.2.3. By Structures
  - 15.2.2.4. By Mode of Action
15.3. Brazil
- 15.3.1. Pricing Analysis
- 15.3.2. Market Share Analysis, 2024
  - 15.3.2.1. By Class
  - 15.3.2.2. By Indication
  - 15.3.2.3. By Structures
  - 15.3.2.4. By Mode of Action
15.4. Mexico
- 15.4.1. Pricing Analysis
- 15.4.2. Market Share Analysis, 2024
  - 15.4.2.1. By Class
  - 15.4.2.2. By Indication
  - 15.4.2.3. By Structures
  - 15.4.2.4. By Mode of Action
15.5. Germany
- 15.5.1. Pricing Analysis
- 15.5.2. Market Share Analysis, 2024
  - 15.5.2.1. By Class
  - 15.5.2.2. By Indication
  - 15.5.2.3. By Structures
  - 15.5.2.4. By Mode of Action
15.6. U.K.
- 15.6.1. Pricing Analysis
- 15.6.2. Market Share Analysis, 2024
  - 15.6.2.1. By Class
  - 15.6.2.2. By Indication
  - 15.6.2.3. By Structures
  - 15.6.2.4. By Mode of Action
15.7. France
- 15.7.1. Pricing Analysis
- 15.7.2. Market Share Analysis, 2024
  - 15.7.2.1. By Class
  - 15.7.2.2. By Indication
  - 15.7.2.3. By Structures
  - 15.7.2.4. By Mode of Action
15.8. Spain
- 15.8.1. Pricing Analysis
- 15.8.2. Market Share Analysis, 2024
  - 15.8.2.1. By Class
  - 15.8.2.2. By Indication
  - 15.8.2.3. By Structures
  - 15.8.2.4. By Mode of Action
15.9. Italy
- 15.9.1. Pricing Analysis
- 15.9.2. Market Share Analysis, 2024
  - 15.9.2.1. By Class
  - 15.9.2.2. By Indication
  - 15.9.2.3. By Structures
  - 15.9.2.4. By Mode of Action
15.10. China
- 15.10.1. Pricing Analysis
- 15.10.2. Market Share Analysis, 2024
  - 15.10.2.1. By Class
  - 15.10.2.2. By Indication
  - 15.10.2.3. By Structures
  - 15.10.2.4. By Mode of Action
15.11. Japan
- 15.11.1. Pricing Analysis
- 15.11.2. Market Share Analysis, 2024
  - 15.11.2.1. By Class
  - 15.11.2.2. By Indication
  - 15.11.2.3. By Structures
  - 15.11.2.4. By Mode of Action
15.12. South Korea
- 15.12.1. Pricing Analysis
- 15.12.2. Market Share Analysis, 2024
  - 15.12.2.1. By Class
  - 15.12.2.2. By Indication
  - 15.12.2.3. By Structures
  - 15.12.2.4. By Mode of Action
15.13. Singapore
- 15.13.1. Pricing Analysis
- 15.13.2. Market Share Analysis, 2024
  - 15.13.2.1. By Class
  - 15.13.2.2. By Indication
  - 15.13.2.3. By Structures
  - 15.13.2.4. By Mode of Action
15.14. Thailand
- 15.14.1. Pricing Analysis
- 15.14.2. Market Share Analysis, 2024
  - 15.14.2.1. By Class
  - 15.14.2.2. By Indication
  - 15.14.2.3. By Structures
  - 15.14.2.4. By Mode of Action
15.15. Indonesia
- 15.15.1. Pricing Analysis
- 15.15.2. Market Share Analysis, 2024
  - 15.15.2.1. By Class
  - 15.15.2.2. By Indication
  - 15.15.2.3. By Structures
  - 15.15.2.4. By Mode of Action
15.16. Australia
- 15.16.1. Pricing Analysis
- 15.16.2. Market Share Analysis, 2024
  - 15.16.2.1. By Class
  - 15.16.2.2. By Indication
  - 15.16.2.3. By Structures
  - 15.16.2.4. By Mode of Action
15.17. New Zealand
- 15.17.1. Pricing Analysis
- 15.17.2. Market Share Analysis, 2024
  - 15.17.2.1. By Class
  - 15.17.2.2. By Indication
  - 15.17.2.3. By Structures
  - 15.17.2.4. By Mode of Action
15.18. GCC Countries
- 15.18.1. Pricing Analysis
- 15.18.2. Market Share Analysis, 2024
  - 15.18.2.1. By Class
  - 15.18.2.2. By Indication
  - 15.18.2.3. By Structures
  - 15.18.2.4. By Mode of Action
15.19. South Africa
- 15.19.1. Pricing Analysis
- 15.19.2. Market Share Analysis, 2024
  - 15.19.2.1. By Class
  - 15.19.2.2. By Indication
  - 15.19.2.3. By Structures
  - 15.19.2.4. By Mode of Action
15.20. Israel
- 15.20.1. Pricing Analysis
- 15.20.2. Market Share Analysis, 2024
  - 15.20.2.1. By Class
  - 15.20.2.2. By Indication
  - 15.20.2.3. By Structures
  - 15.20.2.4. By Mode of Action

16. Market Structure Analysis

16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
- 16.3.1. By Regional
- 16.3.2. By Class
- 16.3.3. By Indication
- 16.3.4. By Structures
- 16.3.5. By Mode of Action

17. Competition Analysis

17.1. Competition Deep Dive
- 17.1.1. Intellihep Ltd
  - 17.1.1.1. Overview
  - 17.1.1.2. Product Portfolio
  - 17.1.1.3. Profitability by Market Segments
  - 17.1.1.4. Sales Footprint
  - 17.1.1.5. Strategy Overview
    - 17.1.1.5.1. Marketing Strategy
- 17.1.2. Protalix Biotherapeutics
  - 17.1.2.1. Overview
  - 17.1.2.2. Product Portfolio
  - 17.1.2.3. Profitability by Market Segments
  - 17.1.2.4. Sales Footprint
  - 17.1.2.5. Strategy Overview
    - 17.1.2.5.1. Marketing Strategy
- 17.1.3. BioMarin Pharmaceutical Inc.
  - 17.1.3.1. Overview
  - 17.1.3.2. Product Portfolio
  - 17.1.3.3. Profitability by Market Segments
  - 17.1.3.4. Sales Footprint
  - 17.1.3.5. Strategy Overview
    - 17.1.3.5.1. Marketing Strategy
- 17.1.4. Sanofi
  - 17.1.4.1. Overview
  - 17.1.4.2. Product Portfolio
  - 17.1.4.3. Profitability by Market Segments
  - 17.1.4.4. Sales Footprint
  - 17.1.4.5. Strategy Overview
    - 17.1.4.5.1. Marketing Strategy
- 17.1.5. Halozyme Therapeutics Inc
  - 17.1.5.1. Overview
  - 17.1.5.2. Product Portfolio
  - 17.1.5.3. Profitability by Market Segments
  - 17.1.5.4. Sales Footprint
  - 17.1.5.5. Strategy Overview
    - 17.1.5.5.1. Marketing Strategy
- 17.1.6. Bayer AG
  - 17.1.6.1. Overview
  - 17.1.6.2. Product Portfolio
  - 17.1.6.3. Profitability by Market Segments
  - 17.1.6.4. Sales Footprint
  - 17.1.6.5. Strategy Overview
    - 17.1.6.5.1. Marketing Strategy
- 17.1.7. Alzheon Inc.
  - 17.1.7.1. Overview
  - 17.1.7.2. Product Portfolio
  - 17.1.7.3. Profitability by Market Segments
  - 17.1.7.4. Sales Footprint
  - 17.1.7.5. Strategy Overview
    - 17.1.7.5.1. Marketing Strategy
- 17.1.8. GlycoMar
  - 17.1.8.1. Overview
  - 17.1.8.2. Product Portfolio
  - 17.1.8.3. Profitability by Market Segments
  - 17.1.8.4. Sales Footprint
  - 17.1.8.5. Strategy Overview
    - 17.1.8.5.1. Marketing Strategy
- 17.1.9. GlaxoSmithKline Plc
  - 17.1.9.1. Overview
  - 17.1.9.2. Product Portfolio
  - 17.1.9.3. Profitability by Market Segments
  - 17.1.9.4. Sales Footprint
  - 17.1.9.5. Strategy Overview
    - 17.1.9.5.1. Marketing Strategy
- 17.1.10. F. Hoffmann-La Roche Ltd
  - 17.1.10.1. Overview
  - 17.1.10.2. Product Portfolio
  - 17.1.10.3. Profitability by Market Segments
  - 17.1.10.4. Sales Footprint
  - 17.1.10.5. Strategy Overview
    - 17.1.10.5.1. Marketing Strategy